Published in Nature on March 24, 2011
Multiple Myeloma Molecular Monitoring Study (M4) | NCT03421132
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
The life history of 21 breast cancers. Cell (2012) 10.59
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Initial impact of the sequencing of the human genome. Nature (2011) 9.18
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell (2012) 4.52
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 3.51
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12
Variation in the mutation rate across mammalian genomes. Nat Rev Genet (2011) 3.09
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet (2014) 2.86
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature (2015) 2.35
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood (2011) 2.28
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics (2011) 2.26
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol (2012) 2.25
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci U S A (2013) 2.23
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell (2015) 2.13
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens. Science (2015) 2.06
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
New strategies in the treatment of multiple myeloma. Clin Cancer Res (2013) 2.05
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia (2013) 2.04
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med (2014) 2.03
DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells. PLoS One (2015) 2.02
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood (2011) 2.01
Diverse mechanisms of somatic structural variations in human cancer genomes. Cell (2013) 2.00
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One (2013) 2.00
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89
Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. Front Microbiol (2012) 1.89
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 1.88
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res (2014) 1.86
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res (2012) 1.82
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol (2011) 1.81
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer (2014) 1.76
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res (2013) 1.70
Genome sequencing and cancer. Curr Opin Genet Dev (2012) 1.68
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol (2013) 1.63
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet (2015) 1.61
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet (2014) 1.58
Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics. J Pathol Inform (2012) 1.58
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia (2014) 1.56
Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood (2014) 1.55
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Reliable identification of genomic variants from RNA-seq data. Am J Hum Genet (2013) 1.55
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer (2011) 1.54
Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med (2012) 1.54
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood (2013) 1.53
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
The mammalian epigenome. Cell (2007) 18.13
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
The molecular classification of multiple myeloma. Blood (2006) 8.77
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity (2003) 5.95
A single subunit, Dis3, is essentially responsible for yeast exosome core activity. Nat Struct Mol Biol (2006) 4.84
Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell (1994) 4.60
The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 4.46
The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol (2008) 4.09
Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 3.93
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
Conservation and evolvability in regulatory networks: the evolution of ribosomal regulation in yeast. Proc Natl Acad Sci U S A (2005) 3.58
Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol (2007) 3.46
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
The exosome: a multipurpose RNA-decay machine. Trends Biochem Sci (2008) 2.40
The exosome subunit Rrp44 plays a direct role in RNA substrate recognition. Mol Cell (2007) 2.18
Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A (1995) 2.13
Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost (2006) 1.88
'Unfolding' pathways in neurodegenerative disease. Trends Neurosci (2003) 1.78
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73
Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res (1991) 1.70
Managing and exploiting stress in the antibody factory. FEBS Lett (2007) 1.48
Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis. Exp Hematol (2003) 1.35
RNA recognition by 3'-to-5' exonucleases: the substrate perspective. Biochim Biophys Acta (2007) 1.27
CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Mol Immunol (2009) 1.26
Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF. Genes Chromosomes Cancer (2008) 1.25
Determination of key residues for catalysis and RNA cleavage specificity: one mutation turns RNase II into a "SUPER-ENZYME". J Biol Chem (2009) 1.22
Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering. BMC Genomics (2007) 1.15
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature (2003) 29.16
GenePattern 2.0. Nat Genet (2006) 29.07
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Transcriptional regulatory code of a eukaryotic genome. Nature (2004) 27.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Natl Acad Sci U S A (2010) 22.97
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
ALLPATHS: de novo assembly of whole-genome shotgun microreads. Genome Res (2008) 20.61
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet (2008) 19.55
Genomic maps and comparative analysis of histone modifications in human and mouse. Cell (2005) 18.96
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83